ClinicalTrials.gg
CompletedNCT06895967Updated Jun 11, 2026Results posted

A Study of TAK-881 and HyQvia in Healthy Adults

A Phase 1 interventional study of TAK-881 and HyQvia in Healthy Volunteers, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Takeda · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The main aim of this study is to understand how the body absorbs, processes, and removes (known as pharmacokinetics or PK) TAK-881 and HyQvia, after they are given as a single injection under the skin in healthy adults.

Study participants will receive a single dose of TAK-881 or HyQvia on Day 1.

During the study, participants will need to stay at the clinic for 8 days followed by 8 ambulatory follow up visits till Day 85.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Drug Therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and Women between 18 and 50 years can participate.
  2. Must be a non-smoker, with no use of nicotine or tobacco products.
  3. Must have (BMI) between 18.0 and 30.0, and body weight under 120 kilograms (kg).
  4. Must be medically healthy.
  5. Must follow protocol-specified guidance.

Exclusion criteria

Exclusion Criteria:

  1. Any current or past medical history of blood/clotting disorder, liver, lung, heart, kidney, immune, skin, or brain or psychiatric condition.
  2. History of alcohol or drug abuse within 2 years before dosing.
  3. History or presence of or severe allergic reactions to blood or blood components.
  4. History or presence of thrombotic/thromboembolic events, or venous thrombosis.
  5. Pregnant or breastfeeding.
  6. Unable to refrain from taking prescription and non-prescription medications, herbal remedies, homeopathic preparations, or vitamin supplements.
  7. Recently donated blood or blood products.
  8. Participated in another clinical trial involving immunoglobulin products within 12 months of screening.
  9. Has taken biologic agents within 12 weeks of screening.
  10. Has used an product within 30 days or 5 half-lives, whichever is longer, prior to screening.
  11. Has received any vaccine (including and COVID-19 vaccines) during the last 30 days before dosing.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    TAK-881 1.0 g/kg

    Participants will receive TAK-881, 1.0 gram per Kilogram (g/kg), single subcutaneous (SC) injection using investigational needle sets on Day 1.

    Biological: TAK-881 · Device: SC Investigational Needle Sets

  • Experimental
    HyQvia 1g/kg

    Participants will receive HyQvia, 1.0 g/kg, single SC injection using investigational needle sets on Day 1.

    Biological: HyQvia · Device: SC Investigational Needle Sets

Interventions

  • BiologicalTAK-881

    Participants will receive SC infusion of TAK-881.

    Also known as: Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20)

  • BiologicalHyQvia

    Drug pages: Immunoglobulin G · Hyaluronoglucosaminidase

    Participants will receive SC infusion of HyQvia.

    Also known as: Immune Globulin Subcutaneous (Human), 10% Solution with rHuPH20

  • DeviceSC Investigational Needle Sets

    The single-use only SC needle set will be used to administer TAK-881 to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.

  • DeviceSC Investigational Needle Sets

    The single-use only SC needle set will be used to administer HyQvia to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.

06

What researchers measure

Primary outcomes

  1. Baseline-corrected Area Under the Concentration-time Curve (AUC) From Day 1 to Day 29 (AUC Day 1-29) Based on Serum Total Immunoglobulin G (IgG) Levels

    Baseline-corrected AUC Day 1-29 based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.

    Time frame: Day 1 up to Day 29

Secondary outcomes

  1. Baseline-uncorrected Maximum Observed Concentration (Cmax) Based on Serum Total IgG Levels

    Baseline-uncorrected Cmax based on serum total IgG levels was reported for TAK-881 and HyQvia.

    Time frame: Day 1 up to Day 85

  2. Baseline-uncorrected Time to Maximum Concentration (Tmax) Based on Serum Total IgG Levels

    Baseline-uncorrected Tmax based on serum total IgG levels was reported for TAK-881 and HyQvia.

    Time frame: Day 1 up to Day 85

  3. Baseline-uncorrected AUC Day1-29 Based on Serum Total IgG Levels

    Baseline-uncorrected AUC Day1-29 based on serum total IgG levels was reported for TAK-881 and HyQvia.

    Time frame: Day 1 up to Day 29

  4. Baseline-corrected AUC From Day 1 to Infinity (AUCinf) Based on Serum Total IgG Levels

    Baseline-corrected AUCinf based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.

    Time frame: Day 1 up to Day 85

  5. Baseline-corrected AUC From Day 1 to Time of the Last Measurable Concentration (AUClast) Based on Serum Total IgG Levels

    Baseline-corrected AUClast based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.

    Time frame: Day 1 up to Day 85

  6. Baseline-corrected Cmax Based on Serum Total IgG Levels

    Baseline-corrected Cmax based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.

    Time frame: Day 1 up to Day 85

  7. Baseline-corrected Tmax Based on Serum Total IgG Levels

    Baseline-corrected Tmax based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.

    Time frame: Day 1 up to Day 85

  8. Baseline-corrected Time of Last Measurable Concentration (Tlast) Based on Serum Total IgG Levels

    Baseline-corrected Tlast based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.

    Time frame: From Day 1 up to Day 85

  9. Baseline-corrected Terminal Half-life (t1/2z) Based on Serum Total IgG Levels

    Baseline-corrected t1/2z based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.

    Time frame: Day 1 up to Day 85

  10. Baseline-corrected Apparent Clearance (CL/F) Based on Serum Total IgG Levels

    Baseline-corrected CL/F based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.

    Time frame: Day 1 up to Day 85

  11. Baseline-corrected Apparent Volume of Distribution (Vz/F) Based on Serum Total IgG Levels

    Baseline-corrected Vz/F based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.

    Time frame: Day 1 up to Day 85

  12. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An Adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was defined as any AE that was starting or worsening at the time of or after dosing of investigational product (IP).

    Time frame: From start of study drug up to end of trial (up to Day 85)

  13. Number of Participants With Infusion Withdrawals, Interruptions, and Infusion Rate Reductions

    The number of participants with infusion withdrawals, interruptions, and infusion rate reductions due to TAK-881 or HyQvia related TEAEs were reported.

    Time frame: On Day 1 (day of the first and only infusion)

  14. Number of Participants With Positive Binding Antibodies to rHuPH20

    Number of participants with positive binding antibodies to recombinant human hyaluronidase (rHuPH20) with titer greater than or equal to (\>=) 1:160 were reported.

    Time frame: At Days -1, 29, and 85

  15. Number of Participants With Neutralizing Antibodies to rHuPH20

    Number of participants with neutralizing antibodies to rHuPH20 were reported.

    Time frame: At Days -1, 29, and 85

07

Results

Posted May 11, 2026

Participant flow

This study was conducted at single center in the United States from 24 March 2025 to 8 August 2025.

Participant flow — Overall Study
MilestoneTAK-881 1.0 g/kgHyQvia 1.0 g/kg
Started1515
Pharmacokinetic per-protocol analysis set (pkppas)1315
Completed1314
Not completed21
Withdrew: Failed drug/alcohol laboratory10
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryBaseline-corrected Area Under the Concentration-time Curve (AUC) From Day 1 to Day 29 (AUC Day 1-29) Based on Serum Total Immunoglobulin G (IgG) Levels

Baseline-corrected AUC Day 1-29 based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.

Time frame:
Day 1 up to Day 29
Reported as:
Geometric mean · gram*hour per liter (g*h/L)
Baseline-corrected Area Under the Concentration-time Curve (AUC) From Day 1 to Day 29 (AUC Day 1-29) Based on Serum Total Immunoglobulin G (IgG) Levels
gram*hour per liter (g*h/L)TAK-881 1.0 g/kgHyQvia 1.0 g/kg
Baseline-corrected Area Under the Concentration-time Curve (AUC) From Day 1 to Day 29 (AUC Day 1-29) Based on Serum Total Immunoglobulin G (IgG) Levels2993 ± 13.63190 ± 25.4
Statistical analysis
  • TAK-881 1.0 g/kg vs HyQvia 1.0 g/kg · t-test, 2 sided · Geometric mean ratio: 93.82 · 95% CI 80.38 to 109.52Two-sample t-test with Welch Satterthwaite correction
SecondaryBaseline-uncorrected Maximum Observed Concentration (Cmax) Based on Serum Total IgG Levels

Baseline-uncorrected Cmax based on serum total IgG levels was reported for TAK-881 and HyQvia.

Time frame:
Day 1 up to Day 85
Reported as:
Geometric mean · gram per liter (g/L)
Baseline-uncorrected Maximum Observed Concentration (Cmax) Based on Serum Total IgG Levels
gram per liter (g/L)TAK-881 1.0 g/kgHyQvia 1.0 g/kg
Baseline-uncorrected Maximum Observed Concentration (Cmax) Based on Serum Total IgG Levels19.84 ± 15.920.70 ± 13.0
SecondaryBaseline-uncorrected Time to Maximum Concentration (Tmax) Based on Serum Total IgG Levels

Baseline-uncorrected Tmax based on serum total IgG levels was reported for TAK-881 and HyQvia.

Time frame:
Day 1 up to Day 85
Reported as:
Median · hours
Baseline-uncorrected Time to Maximum Concentration (Tmax) Based on Serum Total IgG Levels
hoursTAK-881 1.0 g/kgHyQvia 1.0 g/kg
Baseline-uncorrected Time to Maximum Concentration (Tmax) Based on Serum Total IgG Levels167.741 (119.75 to 167.86)143.829 (118.94 to 671.80)
SecondaryBaseline-uncorrected AUC Day1-29 Based on Serum Total IgG Levels

Baseline-uncorrected AUC Day1-29 based on serum total IgG levels was reported for TAK-881 and HyQvia.

Time frame:
Day 1 up to Day 29
Reported as:
Geometric mean · g*h/L
Baseline-uncorrected AUC Day1-29 Based on Serum Total IgG Levels
g*h/LTAK-881 1.0 g/kgHyQvia 1.0 g/kg
Baseline-uncorrected AUC Day1-29 Based on Serum Total IgG Levels10310 ± 13.810720 ± 10.5
SecondaryBaseline-corrected AUC From Day 1 to Infinity (AUCinf) Based on Serum Total IgG Levels

Baseline-corrected AUCinf based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.

Time frame:
Day 1 up to Day 85
Reported as:
Geometric mean · g*h/L
Baseline-corrected AUC From Day 1 to Infinity (AUCinf) Based on Serum Total IgG Levels
g*h/LTAK-881 1.0 g/kgHyQvia 1.0 g/kg
Baseline-corrected AUC From Day 1 to Infinity (AUCinf) Based on Serum Total IgG Levels4556 ± 18.45425 ± 41.4
SecondaryBaseline-corrected AUC From Day 1 to Time of the Last Measurable Concentration (AUClast) Based on Serum Total IgG Levels

Baseline-corrected AUClast based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.

Time frame:
Day 1 up to Day 85
Reported as:
Geometric mean · g*h/L
Baseline-corrected AUC From Day 1 to Time of the Last Measurable Concentration (AUClast) Based on Serum Total IgG Levels
g*h/LTAK-881 1.0 g/kgHyQvia 1.0 g/kg
Baseline-corrected AUC From Day 1 to Time of the Last Measurable Concentration (AUClast) Based on Serum Total IgG Levels4240 ± 21.04591 ± 43.2
SecondaryBaseline-corrected Cmax Based on Serum Total IgG Levels

Baseline-corrected Cmax based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.

Time frame:
Day 1 up to Day 85
Reported as:
Geometric mean · g/L
Baseline-corrected Cmax Based on Serum Total IgG Levels
g/LTAK-881 1.0 g/kgHyQvia 1.0 g/kg
Baseline-corrected Cmax Based on Serum Total IgG Levels8.875 ± 21.29.486 ± 21.8
SecondaryBaseline-corrected Tmax Based on Serum Total IgG Levels

Baseline-corrected Tmax based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.

Time frame:
Day 1 up to Day 85
Reported as:
Median · hours
Baseline-corrected Tmax Based on Serum Total IgG Levels
hoursTAK-881 1.0 g/kgHyQvia 1.0 g/kg
Baseline-corrected Tmax Based on Serum Total IgG Levels167.741 (119.75 to 167.86)143.829 (118.94 to 671.80)
SecondaryBaseline-corrected Time of Last Measurable Concentration (Tlast) Based on Serum Total IgG Levels

Baseline-corrected Tlast based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.

Time frame:
From Day 1 up to Day 85
Reported as:
Median · hours
Baseline-corrected Time of Last Measurable Concentration (Tlast) Based on Serum Total IgG Levels
hoursTAK-881 1.0 g/kgHyQvia 1.0 g/kg
Baseline-corrected Time of Last Measurable Concentration (Tlast) Based on Serum Total IgG Levels2015.748 (575.93 to 2015.84)2015.705 (504.11 to 2016.97)
SecondaryBaseline-corrected Terminal Half-life (t1/2z) Based on Serum Total IgG Levels

Baseline-corrected t1/2z based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.

Time frame:
Day 1 up to Day 85
Reported as:
Median · hours
Baseline-corrected Terminal Half-life (t1/2z) Based on Serum Total IgG Levels
hoursTAK-881 1.0 g/kgHyQvia 1.0 g/kg
Baseline-corrected Terminal Half-life (t1/2z) Based on Serum Total IgG Levels146.613 (42.28 to 454.04)165.913 (37.83 to 951.45)
SecondaryBaseline-corrected Apparent Clearance (CL/F) Based on Serum Total IgG Levels

Baseline-corrected CL/F based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.

Time frame:
Day 1 up to Day 85
Reported as:
Mean · liter per hour (L/h)
Baseline-corrected Apparent Clearance (CL/F) Based on Serum Total IgG Levels
liter per hour (L/h)TAK-881 1.0 g/kgHyQvia 1.0 g/kg
Baseline-corrected Apparent Clearance (CL/F) Based on Serum Total IgG Levels0.01579 ± 0.00298470.01429 ± 0.0050489
SecondaryBaseline-corrected Apparent Volume of Distribution (Vz/F) Based on Serum Total IgG Levels

Baseline-corrected Vz/F based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.

Time frame:
Day 1 up to Day 85
Reported as:
Mean · Liters (L)
Baseline-corrected Apparent Volume of Distribution (Vz/F) Based on Serum Total IgG Levels
Liters (L)TAK-881 1.0 g/kgHyQvia 1.0 g/kg
Baseline-corrected Apparent Volume of Distribution (Vz/F) Based on Serum Total IgG Levels4.169 ± 2.71063.823 ± 2.7628
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An Adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was defined as any AE that was starting or worsening at the time of or after dosing of investigational product (IP).

Time frame:
From start of study drug up to end of trial (up to Day 85)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsTAK-881 1.0 g/kgHyQvia 1.0 g/kg
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)1515
SecondaryNumber of Participants With Infusion Withdrawals, Interruptions, and Infusion Rate Reductions

The number of participants with infusion withdrawals, interruptions, and infusion rate reductions due to TAK-881 or HyQvia related TEAEs were reported.

Time frame:
On Day 1 (day of the first and only infusion)
Reported as:
Count of participants · Participants
Number of Participants With Infusion Withdrawals, Interruptions, and Infusion Rate Reductions
ParticipantsTAK-881 1.0 g/kgHyQvia 1.0 g/kg
Number of Participants With Infusion Withdrawals, Interruptions, and Infusion Rate Reductions00
SecondaryNumber of Participants With Positive Binding Antibodies to rHuPH20

Number of participants with positive binding antibodies to recombinant human hyaluronidase (rHuPH20) with titer greater than or equal to (\>=) 1:160 were reported.

Time frame:
At Days -1, 29, and 85
Reported as:
Count of participants · Participants
Number of Participants With Positive Binding Antibodies to rHuPH20
ParticipantsTAK-881 1.0 g/kgHyQvia 1.0 g/kg
At Day -100
At Day 2900
At Day 8500
SecondaryNumber of Participants With Neutralizing Antibodies to rHuPH20

Number of participants with neutralizing antibodies to rHuPH20 were reported.

Time frame:
At Days -1, 29, and 85
Reported as:
Count of participants · Participants
Number of Participants With Neutralizing Antibodies to rHuPH20
ParticipantsTAK-881 1.0 g/kgHyQvia 1.0 g/kg
At Day -100
At Day 2900
At Day 8500

Adverse events

Collected over From start of study drug up to end of trial (up to Day 85). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TAK-881 1.0 g/kg0/15 (0%)0/15 (0%)15/15 (100%)
HyQvia 1.0 g/kg0/15 (0%)0/15 (0%)15/15 (100%)
Most frequent other events
Showing 10 of 55
Most frequent other events
EventTAK-881 1.0 g/kgHyQvia 1.0 g/kg
Infusion site erythemaGeneral disorders14/1515/15
Infusion site swellingGeneral disorders15/1514/15
Infusion site pruritusGeneral disorders8/1511/15
HeadacheNervous system disorders9/159/15
Infusion site painGeneral disorders8/159/15
Feeling hotGeneral disorders4/155/15
HyperhidrosisSkin and subcutaneous tissue disorders0/154/15
Infusion site discomfortGeneral disorders1/154/15
ChillsGeneral disorders3/152/15
NauseaGastrointestinal disorders2/153/15

Baseline characteristics

Safety analysis set included all participants who received any amount of TAK-881 or HyQvia.

Age, Continuous
Age, Continuous(years)TAK-881 1.0 g/kgHyQvia 1.0 g/kgTotal
Mean34.9 ± 9.1438.3 ± 6.9836.6 ± 8.18
Sex: Female, Male
Sex: Female, Male(Participants)TAK-881 1.0 g/kgHyQvia 1.0 g/kgTotal
Female121022
Male358
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TAK-881 1.0 g/kgHyQvia 1.0 g/kgTotal
Hispanic or Latino141529
Not Hispanic or Latino101
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TAK-881 1.0 g/kgHyQvia 1.0 g/kgTotal
American Indian or Alaska Native101
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American303
White111526
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Celerion
    Tempe, Arizona 85283, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in Jul 2025, 4 months.

Results were first posted in May 2026, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2025
First posted
Mar 26, 2025
StartActual
Mar 24, 2025
Primary completionActual
Jul 24, 2025
CompletionActual
Aug 8, 2025
Results first posted
May 11, 2026
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06895967
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 26, 2025
Start date
Mar 24, 2025
Primary completion
Jul 24, 2025
Completion
Aug 8, 2025
Results posted
May 11, 2026
Last update
Jun 11, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Immunoglobulins, Intravenous · Immunoglobulin G · Hyaluronoglucosaminidase

Start the discussion